ClinicalTrials.Veeva

Menu

Entacapone Augmentation for Schizophrenia

R

Rambam Health Care Campus

Status

Completed

Conditions

Schizophrenia

Treatments

Drug: Entacapone

Study type

Interventional

Funder types

Other

Identifiers

NCT00192855
entacapon.schiz.CTIL

Details and patient eligibility

About

This study is testing the hypothesis that Entacapone added to ongoing antipsychotic treatment can be beneficial in schizophrenic patients with negative symptoms.

Enrollment

52 patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • predominantly negative symptoms
  • stable on ongoing antipsychotic treatment

Exclusion criteria

  • acute psychotic exacerbation
  • suicidal ideation
  • uncontrolled systemic disease

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Factorial Assignment

Masking

Double Blind

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems